Fasoracetam
From Wikipedia, the free encyclopedia
|
|||
| Names | |||
|---|---|---|---|
| IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one
|
|||
| Other names
(5R)-5-oxo-D-prolinepiperidinamide
|
|||
| Identifiers | |||
110958-19-5  |
|||
| 3D model (Jmol) | Interactive image | ||
| ChEMBL | ChEMBL2106179  |
||
| ChemSpider | 171980 |
||
| KEGG | C13311 |
||
| PubChem | 198695 | ||
|
|||
|
|||
| Properties | |||
| C10H16N2O2 | |||
| Molar mass | 196.25 g·mol−1 | ||
| Pharmacology | |||
| Oral | |||
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|||
 verify (what is ?) |
|||
| Infobox references | |||
Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate)[1] is a research chemical of the racetam family.[2] It is a nootropic, and has been in a clinical trial for attention deficit hyperactivity disorder.[3]
In in vitro studies on mouse neurons, fasoracetam modulated mGluR II/III activity.[4] In studies in rats, it blocked memory disruptions caused by baclofen, a GABAB agonist[5] and upregulated production of GABAB receptors after repeat dosing.[6]
References[edit]
- ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
- ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
- ^ "Drug Profile Fasoracetam".
- ^ Oka, M; Itoh, Y; Tatsumi, S; Ma, FH; Ukai, Y; Yoshikuni, Y; Kimura, K. "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture.". Naunyn Schmiedebergs Arch Pharmacol. 356: 189–96. doi:10.1007/pl00005040. PMID 9272724..
- ^ Ogasawara, T; Itoh, Y; Tamura, M; Mushiroi, T; Ukai, Y; Kise, M; Kimura, K. "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.". Pharmacol Biochem Behav. 64: 41–52. doi:10.1016/s0091-3057(99)00108-2. PMID 10494996.
- ^ Shimidzu, T; Itoh, Y; Oka, M; Ishima, T; Ukai, Y; Yoshikuni, Y; Kimura, K. "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment.". Eur J Pharmacol. 338: 225–32. doi:10.1016/s0014-2999(97)81925-5. PMID 9424016.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
